Causal relationship between inflammatory factors and gynecological cancer: a Bayesian Mendelian randomization study

被引:3
作者
Dang, Chunxiao [1 ]
Liu, Mengmeng [2 ]
Liu, Pengfei [1 ]
Liu, Jinxing [1 ]
Yu, Xiao [3 ]
Dong, Yan [4 ]
Zhao, Junde [5 ]
机构
[1] Shandong Univ Tradit Chinese Med, Clin Med Coll 1, Jinan 250014, Peoples R China
[2] Shandong Prov Hosp Grp, Dongying Peoples Hosp, Dongying Hosp, Dongying 257000, Peoples R China
[3] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Gynecol, Jinan 250014, Peoples R China
[4] Shandong Univ Tradit Chinese Med, Affiliated Hosp 2, Dept Obstet & Gynecol, Jingba Rd 1, Jinan 250014, Peoples R China
[5] Shandong Univ Tradit Chinese Med, Jingshi Rd 16369, Jinan 250014, Peoples R China
关键词
Circulating inflammatory factors; Cervical cancer; Ovarian cancer; Endometrial cancer; Mendelian randomization; COLONY-STIMULATING FACTOR; ENDOMETRIAL CANCER; TUMOR PROGRESSION; CELLS; EXPRESSION; PATHWAYS; INDEXES; GROWTH; GENES; RISK;
D O I
10.1038/s41598-024-80747-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Cervical cancer, ovarian cancer, and endometrial cancer are the three most common cancers in gynecology. Understanding their respective pathology is currently incomplete. Inflammatory factors play an important role in the pathophysiology of these three cancers, but the causal relationship between inflammatory factors and these three cancers is unclear. Methods: Based on publicly available genetic databases, relevant instrumental variables were extracted according to predefined thresholds, and causal analyses of CRP, 41 circulating inflammatory factors, and three gynecological cancers were performed, mainly using the inverse variance weighted method, while bayesian analysis was performed to improve the accuracy of the results. Finally, heterogeneity, horizontal pleiotropy test, and MR Steiger test were carried out to evaluate the reliability of the findings and the causal inference strength. Results: One inflammatory factor (PDGF-BB) and four inflammatory factors (CXCL9, IL-6, CXCL1, and G-CSF) were identified as significantly associated with the risk of ovarian and endometrial cancers, respectively. In comparison, cervical cancer was found to have a negative causal association with one inflammatory factor (G-CSF) and endometrial cancer with two inflammatory factors (CXCL10 and CCL11). Conclusions: Our MR study suggests potential causal relationships between circulating inflammatory regulators and three gynecological cancers from a genetic perspective, which contributes to further understanding of the pathomechanisms of cervical, ovarian and endometrial cancers and highlights the potential of targeting inflammatory factors as therapeutic interventions and predictors
引用
收藏
页数:8
相关论文
共 56 条
[1]   Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors [J].
Ahola-Olli, Ari V. ;
Wurtz, Peter ;
Havulinna, Aki S. ;
Aalto, Kristiina ;
Pitkanen, Niina ;
Lehtimaki, Terho ;
Kahonen, Mika ;
Lyytikainen, Leo-Pekka ;
Raitoharju, Emma ;
Seppala, Ilkka ;
Sarin, Antti-Pekka ;
Ripatti, Samuli ;
Palotie, Aarne ;
Perola, Markus ;
Viikari, Jorma S. ;
Jalkanen, Sirpa ;
Maksimow, Mikael ;
Salomaa, Veikko ;
Salmi, Marko ;
Kettunen, Johannes ;
Raitakari, Olli T. .
AMERICAN JOURNAL OF HUMAN GENETICS, 2017, 100 (01) :40-50
[2]   A role for G-CSF and GM-CSF in nonmyeloid cancers [J].
Aliper, Alexander M. ;
Frieden-Korovkina, Victoria P. ;
Buzdin, Anton ;
Roumiantsev, Sergey A. ;
Zhavoronkov, Alex .
CANCER MEDICINE, 2014, 3 (04) :737-746
[3]   Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement [J].
Bharti, Rashmi ;
Dey, Goutam ;
Mandal, Mahitosh .
CANCER LETTERS, 2016, 375 (01) :51-61
[4]   Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors [J].
Burgess, Stephen ;
Scott, Robert A. ;
Timpson, Nicholas J. ;
Smith, George Davey ;
Thompson, Simon G. .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2015, 30 (07) :543-552
[5]   Mendelian randomisation for mediation analysis: current methods and challenges for implementation [J].
Carter, Alice R. ;
Sanderson, Eleanor ;
Hammerton, Gemma ;
Richmond, Rebecca C. ;
Davey Smith, George ;
Heron, Jon ;
Taylor, Amy E. ;
Davies, Neil M. ;
Howe, Laura D. .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2021, 36 (05) :465-478
[6]   ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer-Update 2023 [J].
Cibula, David ;
Raspollini, Maria Rosaria ;
Centeno, Carlos ;
Planchamp, Francois ;
Chargari, Cyrus ;
Felix, Ana ;
Fischerova, Daniela ;
Jahnn-Kuch, Daniela ;
Joly, Florence ;
Kohler, Christhardt ;
Lax, Sigurd ;
Lorusso, Domenica ;
Mahantshetty, Umesh ;
Mathevet, Patrice ;
Naik, Mr Raj ;
Nout, Remi A. ;
Oaknin, Ana ;
Peccatori, Fedro ;
Persson, Jan ;
Querleu, Denis ;
Rubio Bernabe, Sandra ;
Schmid, Maximilian P. ;
Stepanyan, Artem ;
Svintsitskyi, Valentyn ;
Tamussino, Karl ;
Zapardiel, Ignacio ;
Lindegaard, Jacob Christian .
RADIOTHERAPY AND ONCOLOGY, 2023, 184
[7]  
DEMETRI GD, 1989, BLOOD, V74, P940
[8]   A review of the pleiotropic actions of the IFN-inducible CXC chemokine receptor 3 ligands in the synovial microenvironment [J].
Dillemans, Luna ;
De Somer, Lien ;
Neerinckx, Barbara ;
Proost, Paul .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2023, 80 (03)
[9]  
Du Hongyan, 2016, Zhonghua Yi Xue Za Zhi, V96, P358, DOI 10.3760/cma.j.issn.0376-2491.2016.05.009
[10]   Classical Prognostic Factors Predict Prognosis Better than Inflammatory Indices in Locally Advanced Cervical Cancer: Results of a Comprehensive Observational Study including Tumor-, Patient-, and Treatment-Related Data (ESTHER Study) [J].
Ferioli, Martina ;
Benini, Anna ;
Malizia, Claudio ;
Forlani, Ludovica ;
Medici, Federica ;
Laghi, Viola ;
Ma, Johnny ;
Galuppi, Andrea ;
Cilla, Savino ;
Buwenge, Milly ;
Macchia, Gabriella ;
Zamagni, Claudio ;
Tagliaferri, Luca ;
Perrone, Anna Myriam ;
De Iaco, Pierandrea ;
Strigari, Lidia ;
Morganti, Alessio Giuseppe ;
Arcelli, Alessandra .
JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (08)